NCT03730012View on ClinicalTrials.gov

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

May 14, 2021

Study Completion Date

June 15, 2021

Conditions
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions
DRUG

gilteritinib

Oral tablet

DRUG

atezolizumab

Intravenous infusion

Trial Locations (12)

10032

Columbia University Medical Center, New York

10065

Weill Cornell Medical College, New York

14263

Roswell Park Cancer Institute (RPCI), Buffalo

37232

Vanderbilt Ingram Cancer Center, Nashville

40536

University of Kentucky, Lexington

43210

The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus

53226

Medical College of Wisconsin, Milwaukee

60037

University of Chicago, Chicago

60611

Northwestern University, Chicago

75390

Simmons Comprehensive Cancer Center, Dallas

77030

University of Texas MD Anderson, Houston

90095

Ronald Reagan UCLA Medical Center, Los Angeles

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03730012 - A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter